Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
MT newswire2026/10/07 13:2709:27 AM EDT, 10/07/2026 (MT Newswires) -- Ultragenyx Pharmaceutical (RARE) said Wednesday it has signed a definitive agreement to sell a rare pediatric disease priority review voucher for $210 million. The company had received the voucher after the US Food and Drug Administration approved Genglycos to treat the underlying cause of glycogen storage disease type Ia, according to a statement. The company said the transaction is subject to customary conditions, including the expiration of the Hart-Scott Rodino waiting period.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SNT Holdings, Related Party Raise Combined Stake in SNTEnergy to 55.75% From 52.75%
Cold wave and rising fuel costs drive electricity prices in northeastern Japan and Tokyo to a four-year high
Japan's spot electricity prices surged to multi-year highs over the weekend.
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail
Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.
Canaccord Genuity: Lowers Oklo's target price to $66
Crypto prices
More
